.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,157,466

« Back to Dashboard
Patent 7,157,466 protects TYKERB and is included in one NDA. There has been one Paragraph IV challenge on Tykerb.

This patent has forty-four patent family members in twenty-six countries.

Summary for Patent: 7,157,466

Title:Quinazoline ditosylate salt compounds
Abstract:Ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorde4rs characterized by aberrant erbB family PTK activity.
Inventor(s): McClure; Michael Scott (Durham, NC), Osterhout; Martin Howard (Durham, NC), Roschangar; Frank (Glen Allen, VA), Sacchetti; Mark Joseph (Foster City, CA)
Assignee: SmithKline Beecham (Cork) Limited (IE)
Application Number:10/311,678
Patent Claim Types:
see list of patent claims
Compound; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 9th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
TYKERB
lapatinib ditosylate
TABLET;ORAL022059-001Mar 13, 2007RXYes7,157,466► subscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,157,466

PCT Information
PCT FiledJune 28, 2001PCT Application Number:PCT/US01/20706
PCT Publication Date:January 10, 2002PCT Publication Number: WO02/02552

International Patent Family for Patent: 7,157,466

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1294715► subscribe
Poland204958► subscribe
Poland365637► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc